25.12.2014 Views

ADVAIR DISKUS ADVAIR - GlaxoSmithKline

ADVAIR DISKUS ADVAIR - GlaxoSmithKline

ADVAIR DISKUS ADVAIR - GlaxoSmithKline

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Over the 3 year treatment period of study SCO30003, FEV 1 values were also higher in<br />

patients treated with <strong>ADVAIR</strong> ® <strong>DISKUS</strong> ® 50/500 mcg than for those treated with<br />

placebo (average difference over 3 years 92 mL, 95% CI: 75 to 108 mL; p < 0.001).<br />

<strong>ADVAIR</strong> ® <strong>DISKUS</strong> ® was also more effective than salmeterol or fluticasone propionate<br />

in improving FEV 1 (average difference over 3 years 50 mL, p < 0.001 for salmeterol and<br />

44 mL, p < 0.001 for fluticasone propionate). Averaged over the 3 years of the study,<br />

patients treated with <strong>ADVAIR</strong> ® <strong>DISKUS</strong> ® showed a +29 mL increase from baseline in<br />

post-bronchodilator FEV 1 while the placebo, salmeterol and fluticasone propionate<br />

groups demonstrated a decline of -62 mL, -21 mL, and -15 mL, respectively.<br />

TOXICOLOGY<br />

Note: For complete information on the toxicology of the individual compounds<br />

salmeterol xinafoate and fluticasone propionate, please refer to the SEREVENT ® and<br />

FLOVENT ® Product Monographs.<br />

Acute Toxicity<br />

The experimental details of single dose studies are presented below:<br />

Species<br />

(strain)<br />

Route of<br />

Administration<br />

Nominal Exposure<br />

Concentrations (mcg/L)<br />

(Salmeterol xinafoate:<br />

Fluticasone propionate)<br />

Initial<br />

Group<br />

M<br />

F<br />

Duration<br />

of Treatment<br />

(Days)<br />

Rat<br />

(Wistar)<br />

Inhalation<br />

(dry powder)<br />

0:0<br />

75:40<br />

0:0<br />

10:20<br />

20:40<br />

10 10<br />

10 10<br />

5 5<br />

5 5<br />

5 5<br />

1<br />

Rat<br />

(Wistar)<br />

Inhalation<br />

(dry powder)<br />

0:0<br />

1:2<br />

2:4<br />

5:10<br />

10:20<br />

20:40<br />

7 7<br />

7 7<br />

7 7<br />

7 7<br />

7 7<br />

7 7<br />

1<br />

Rat<br />

(Wistar)<br />

Inhalation<br />

(dry power)<br />

0:0<br />

75:0<br />

75:40<br />

10 0<br />

10 0<br />

10 0<br />

1<br />

High single inhaled doses of combinations of salmeterol xinafoate and fluticasone<br />

propionate were well-tolerated by rats. With one exception (mild atrial myocarditis), all<br />

findings were expected at the doses of salmeterol xinafoate and fluticasone propionate<br />

administered.<br />

Mild atrial myocarditis occurred at combination doses of 28 mcg/kg salmeterol with<br />

73 mcg/kg fluticasone propionate, or higher, at which plasma drug concentrations were at<br />

least 30 times (salmeterol) or 26 times (fluticasone propionate) greater than peak levels in<br />

July 29, 2014<br />

Page 48 of 67

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!